Research
We are driving the next generation of discoveries to address critical cancer challenges and accelerate the translation of scientific evidence into patient benefit.
Education
Fostering an outstanding cancer care workforce to help maintain and enhance world-leading patient outcomes through online learning, courses and events.
Health Equity
Pursuing equity in access to cancer care and outcomes for all Victorians affected by cancer.
Consumer Engagement
Partnering with consumers at every step of our journey, because no-one knows cancer like someone who’s lived it.
About Us
Research, academic and clinical institutions working together to accelerate cancer research, knowledge and expertise to benefit all.
News & Events
The VCCC Alliance brings you the latest in cancer research, education and clinical care through engaging, relevant and informative events.

Sponsor-Investigator

The Sponsor-Investigator fulfils the responsibilities of both Sponsor and Investigator as per the TGA: ICH Guideline for Good Clinical Practice (GCP).

The functions of the Sponsor-Investigator, specifically for investigator-initiated trials, include:

  • Securing funding for the clinical trial
  • Generating clinical trial documentation, such as informed consent, protocols, as well as submissions, for example, ethics and/or regulatory submissions
  • Ensuring adequate resources are available for the duration of the trial, such as experienced staff, investigational products, clinical and medical supplies, central laboratory
  • Creating appropriate written procedures, such as standard operating procedures (SOPs), related to Good Clinical Practice (GCP)
  • Meeting all the applicable regulatory requirements such as obtaining and maintaining necessary approvals from the relevant ethics committees and regulatory agencies
  • Managing essential documents using a Trial Master File (TMF)
  • Acknowledging those who have contributed to the clinical trial, and cite and acknowledge other relevant work appropriately and accurately
  • Participating in peer review in a way that is fair, rigorous and timely and maintains the confidentiality of the content
  • Adopting methods appropriate to the aims of the clinical trial and ensure that conclusions are justified by the results
  • Disseminating clinical trial findings responsibly, accurately and broadly. Where necessary, take action to correct the record in a timely manner
  • Ensuring that authors of clinical trial outputs are all those, and only those, who have made a significant intellectual or scholarly contribution to the clinical trial and its output, and that they agree to be listed as an author

Get the latest in cancer news, events and more, direct to your inbox

Join a network of Victorian cancer researchers, clinicians and consumers to keep your finger on the pulse.